<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Medicare</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>340B provider finds new way into court over Rx price disputes </title>
      <description>
        <![CDATA[Even though case law has established that 340B-covered providers can’t sue drug companies for overcharging on the steeply discounted drugs, the Adventist Health System of West tried a new door into court – as a whistleblower under the False Claims Act.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729559</guid>
      <pubDate>Wed, 18 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729559-340b-provider-finds-new-way-into-court-over-rx-price-disputes</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Legal-scales-and-clipboard.webp?t=1773867848" type="image/jpeg" medium="image" fileSize="372138">
        <media:title type="plain">Legal scales and clipboard</media:title>
      </media:content>
    </item>
    <item>
      <title>CMS rewrites organ procurement rule to expand availability</title>
      <description>
        <![CDATA[A new draft guidance for organ procurement organizations doing business in the U.S. would seem to tackle some pressing issues with organ donation, such as the conditions in which a problem qualifies as an adverse event. Perhaps of greater interest to companies in the organ container business is that the Centers for Medicare & Medicaid Services is intent on increasing the availability of organ donations to deal with an insatiable demand for donated organs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728282</guid>
      <pubDate>Fri, 30 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728282-cms-rewrites-organ-procurement-rule-to-expand-availability</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/CMS-medicare-reimbursement.webp?t=1588869757" type="image/png" medium="image" fileSize="1528480">
        <media:title type="plain">Medicare puzzle</media:title>
      </media:content>
    </item>
    <item>
      <title>US CMS names its choices for third round of price negotiations</title>
      <description>
        <![CDATA[The pressure on U.S. drug prices continues, with the CMS lining up the drugs for round 3 of negotiations, which will set maximum fair prices to go into effect in 2028. The slate includes 15 drugs and, for the first time, opens the negotiations to Part B drugs, as well as Part D. Consequently, seven of the 15 selected drugs are biologics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728341</guid>
      <pubDate>Wed, 28 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728341-us-cms-names-its-choices-for-third-round-of-price-negotiations</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Drug-capsule-and-dollar-sign.webp?t=1617651432" type="image/png" medium="image" fileSize="186891">
        <media:title type="plain">Drug capsule and dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Zynex officials indicted for health care fraud</title>
      <description>
        <![CDATA[The U.S. Department of Justice reported that it has indicted two executives with Zynex Inc. for Medicare fraud, but in one of the stranger twists in recent fraud cases, one of the executives allegedly attempted to interfere with the personal lives of members of the media who were reporting on the company’s legal problems.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728242</guid>
      <pubDate>Mon, 26 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728242-zynex-officials-indicted-for-health-care-fraud</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Decorative-scales-of-justice-in-a-courtroom.webp?t=1755117951" type="image/jpeg" medium="image" fileSize="658777">
        <media:title type="plain">Decorative scales of justice in a courtroom</media:title>
      </media:content>
    </item>
    <item>
      <title>FY 2025 a banner year for US False Claims Act recoveries</title>
      <description>
        <![CDATA[The U.S. Department of Justice said recoveries under the False Claims Act in fiscal year 2025 reached a record of more than $6.8 billion, more than 80% of which came from health care cases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728053</guid>
      <pubDate>Tue, 20 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728053-fy-2025-a-banner-year-for-us-false-claims-act-recoveries</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Decorative-scales-of-justice-in-a-courtroom.webp?t=1755117951" type="image/jpeg" medium="image" fileSize="658777">
        <media:title type="plain">Decorative scales of justice in a courtroom</media:title>
      </media:content>
    </item>
    <item>
      <title>Medicare improper payment rate down in FY 2025</title>
      <description>
        <![CDATA[The U.S. Centers for Medicare & Medicaid Services announced Jan. 15 that the estimated volume of improper payments for Medicare fee-for-service care in fiscal 2025 was nearly $29 billion while the number for Medicare managed care was in excess of $23 billion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728052</guid>
      <pubDate>Tue, 20 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728052-medicare-improper-payment-rate-down-in-fy-2025</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/CMS-medicare-reimbursement.webp?t=1588869757" type="image/png" medium="image" fileSize="1528480">
        <media:title type="plain">Medicare puzzle</media:title>
      </media:content>
    </item>
    <item>
      <title>CMS hears discord in comments for TAVR coverage memo</title>
      <description>
        <![CDATA[The Centers for Medicare & Medicaid Services has cracked open its coverage policy for transcatheter aortic valve replacement devices a second time, and a wide range of stakeholders are providing feedback. Where the agency will land on questions such as the need for continued evidence development is difficult to predict, however, given that the agency is hearing anything but unanimity on the question.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727841</guid>
      <pubDate>Fri, 16 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727841-cms-hears-discord-in-comments-for-tavr-coverage-memo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/CMS-medicare-reimbursement.webp?t=1588869757" type="image/png" medium="image" fileSize="1528480">
        <media:title type="plain">Medicare puzzle</media:title>
      </media:content>
    </item>
    <item>
      <title>White House continues to stomp down on US drug prices – for some</title>
      <description>
        <![CDATA[Then there were three. With the administration’s Dec. 19 announcement of most-favored-nation (MFN) pricing deals with nine more biopharmas, only three of the 17 companies on the receiving end of U.S. President Donald Trump’s July 31 MFN ultimatum have yet to finalize terms with the White House – Abbvie Inc., Johnson & Johnson (J&J) and Regeneron Pharmaceuticals Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727341</guid>
      <pubDate>Mon, 22 Dec 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727341-white-house-continues-to-stomp-down-on-us-drug-prices-for-some</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Medicine-and-money.webp?t=1693342143" type="image/jpeg" medium="image" fileSize="139920">
        <media:title type="plain">Pills spilling out of bottle onto money</media:title>
      </media:content>
    </item>
    <item>
      <title>Gimme shelter: Neurocrine, Lilly spared in CMS price cut fallout</title>
      <description>
        <![CDATA[The U.S. Centers for Medicare & Medicaid Services (CMS) rolled out negotiated costs of the second batch of drugs subject to such bargaining under the Inflation Reduction Act. Wall Street was not surprised to learn that the numbers amount to much greater cuts than the Biden administration managed for 2026. CMS said the adjusted maximum fair prices would have achieved 44% lower net spending had they been implemented in 2024 – 36% if forgiven discounts from the part D redesign of the Medicare prescription drug benefit are figured in. Fifteen drugs are listed.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726506</guid>
      <pubDate>Wed, 26 Nov 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726506-gimme-shelter-neurocrine-lilly-spared-in-cms-price-cut-fallout</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/White-tabletl-with-dollar-sign-imprint.webp?t=1764186016" type="image/jpeg" medium="image" fileSize="192346">
        <media:title type="plain">White tablet imprinted with dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>OIG sees potential for savings in Medicare CGM coverage</title>
      <description>
        <![CDATA[The Office of Inspector General issued a report stating that the Medicare program could save “tens of millions of dollars” in a single year on continuous glucose monitors and associated supplies if the Centers for Medicare & Medicaid Services acted to apply price pressure on suppliers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726404</guid>
      <pubDate>Wed, 26 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726404-oig-sees-potential-for-savings-in-medicare-cgm-coverage</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/CMS-medicare-reimbursement.webp?t=1588869757" type="image/png" medium="image" fileSize="1528480">
        <media:title type="plain">Medicare puzzle</media:title>
      </media:content>
    </item>
    <item>
      <title>Cardiology societies laud Medicare coverage of EP procedures at ASCs</title>
      <description>
        <![CDATA[The U.S. Centers for Medicare & Medicaid Services will cover certain cardiac electrophysiology procedures in ambulatory surgical centers in 2026. This change which drew the support of both the Heart Rhythm Society and the American College of Cardiology, which could increase device utilization.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726403</guid>
      <pubDate>Wed, 26 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726403-cardiology-societies-laud-medicare-coverage-of-ep-procedures-at-ascs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/CMS-logo-and-website.webp?t=1689968782" type="image/jpeg" medium="image" fileSize="122536">
        <media:title type="plain">CMS logo and website</media:title>
      </media:content>
    </item>
    <item>
      <title>CMS terminates Treatment Choices model in ESRD final rule</title>
      <description>
        <![CDATA[The U.S. Centers for Medicare & Medicaid Services ended the Treatment Choices model under the end stage renal disease payment payment system for several reasons, including its failure to deliver meaningful savings.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726393</guid>
      <pubDate>Tue, 25 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726393-cms-terminates-treatment-choices-model-in-esrd-final-rule</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/CMS-logo-and-website.webp?t=1689968782" type="image/jpeg" medium="image" fileSize="122536">
        <media:title type="plain">CMS logo and website</media:title>
      </media:content>
    </item>
    <item>
      <title>CMS finalizes plan to do away with inpatient-only list</title>
      <description>
        <![CDATA[The U.S. Centers for Medicare & Medicaid Services released the 1657-page final rule for inpatient payment for calendar year 2026, a document chock full of important policy decisions including a renewed call for elimination of the inpatient-only list.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726384</guid>
      <pubDate>Mon, 24 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726384-cms-finalizes-plan-to-do-away-with-inpatient-only-list</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/CMS-logo-and-website.webp?t=1689968782" type="image/jpeg" medium="image" fileSize="122536">
        <media:title type="plain">CMS logo and website</media:title>
      </media:content>
    </item>
    <item>
      <title>PAMA cuts for clinical lab testing averted, but overhang remains</title>
      <description>
        <![CDATA[The resolution of the budget impasse between Democrats and Republicans on Capitol Hill sidestepped a number of problems, including some cuts to Medicare payment rates for clinical laboratory testing services. However, that pause is only in effect through the end of January 2026, leaving operators of these labs with a fiscal sword of Damocles to manage.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726217</guid>
      <pubDate>Thu, 20 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726217-pama-cuts-for-clinical-lab-testing-averted-but-overhang-remains</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/US-Capitol-at-night.webp?t=1759269324" type="image/jpeg" medium="image" fileSize="854186">
        <media:title type="plain">US Capitol at night</media:title>
      </media:content>
    </item>
    <item>
      <title>Partisan rhetoric heats up in Rx price-lowering jousting</title>
      <description>
        <![CDATA[In a verbal sparring over who can deliver the lowest drug prices in the U.S., several Senate Democrats are urging President Donald Trump to immediately release the list of second-round Medicare-negotiated drug prices, instead of doing what they characterize as “ambiguous” and “opaque” pricing deals with individual biopharma companies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726261</guid>
      <pubDate>Wed, 19 Nov 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726261-partisan-rhetoric-heats-up-in-rx-price-lowering-jousting</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Drug-prices-pills-cash.webp?t=1588782562" type="image/png" medium="image" fileSize="492078">
        <media:title type="plain">Money and pills</media:title>
      </media:content>
    </item>
    <item>
      <title>WISeR model said to create incentives to deny claims</title>
      <description>
        <![CDATA[The Medicare Wasteful and Inappropriate Service Reduction (WISeR) proposal is designed to tamp down on waste, fraud and abuse in the Medicare program, but Jeff Wurzberg, a partner at Norton Rose Fulbright LLP, told <em>BioWorld</em> that the contractors developing these AI models have incentives to return non-covered determinations for services.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726189</guid>
      <pubDate>Mon, 17 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726189-wiser-model-said-to-create-incentives-to-deny-claims</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/CMS-logo-and-website.webp?t=1689968782" type="image/jpeg" medium="image" fileSize="122536">
        <media:title type="plain">CMS logo and website</media:title>
      </media:content>
    </item>
    <item>
      <title>Lilly, Novo MFN deals expected to ‘democratize’ obesity drugs</title>
      <description>
        <![CDATA[Hailing it as a win-win and a historic step forward in fighting chronic disease, the Trump administration announced pricing agreements Nov. 6 with Eli Lilly and Co. and Novo Nordisk A/S that will expand the availability of the companies’ weight loss drugs by cutting prices and, for the first time, providing coverage for the drugs in obesity through Medicare and Medicaid.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725874</guid>
      <pubDate>Thu, 06 Nov 2025 10:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725874-lilly-novo-mfn-deals-expected-to-democratize-obesity-drugs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Wegovy-and-Zepbound-autoinjectors.webp?t=1762469654" type="image/jpeg" medium="image" fileSize="310491">
        <media:title type="plain">Wegovy and Zepbound autoinjectors</media:title>
        <media:description type="plain">Credit: Novo Nordisk A/S and Eli Lilly and Co.</media:description>
      </media:content>
    </item>
    <item>
      <title>CMS reduces required term of medical therapy in RDN final memo</title>
      <description>
        <![CDATA[The U.S. CMS has confirmed that it will cover renal denervation as a treatment for hypertension in a final coverage memo that largely mirrors the July 2025 draft. One key difference, however, is that Medicare beneficiaries are eligible for RDN after only six weeks of optimized medical therapy, half the three-month waiting period described in the draft.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725520</guid>
      <pubDate>Wed, 05 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725520-cms-reduces-required-term-of-medical-therapy-in-rdn-final-memo</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/3-30-Medtronic-Symplicity-Spyral.webp?t=1585605773" type="image/png" medium="image" fileSize="358899">
        <media:title type="plain">3-30-Medtronic-Symplicity-Spyral.png</media:title>
        <media:description type="plain">Symplicity Spyral renal denervation system. Credit: Medtronic plc</media:description>
      </media:content>
    </item>
    <item>
      <title>Skin substitutes take a hit in Medicare doc fee final for 2026</title>
      <description>
        <![CDATA[The U.S. CMS has adopted an aggressive payment policy for skin substitutes in the Medicare physician fee schedule for 2026, although the payment rate is sufficiently higher than the agency had proposed to mollify some critics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725501</guid>
      <pubDate>Mon, 03 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725501-skin-substitutes-take-a-hit-in-medicare-doc-fee-final-for-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/CMS-medicare-reimbursement.webp?t=1588869757" type="image/png" medium="image" fileSize="1528480">
        <media:title type="plain">Medicare puzzle</media:title>
      </media:content>
    </item>
    <item>
      <title>OIG sees continuing problems with DME payments</title>
      <description>
        <![CDATA[The Office of Inspector General (OIG) said in a new report that the U.S. Medicare program had overpaid a group of providers of durable medical equipment (DME) by nearly $23 million between 2018 and 2024, an amount that is a significant drop from prior years, but which OIG said calls for further reforms for the Medicare DME program.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725499</guid>
      <pubDate>Mon, 03 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725499-oig-sees-continuing-problems-with-dme-payments</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Inspection-illustration.webp?t=1663879682" type="image/png" medium="image" fileSize="252293">
        <media:title type="plain">Magnifying glass atop paperwork</media:title>
      </media:content>
    </item>
    <item>
      <title>BioFuture 2025: The challenge of accurate drug pricing</title>
      <description>
        <![CDATA[Government and market demands on companies and their pricing strategies have shifted dramatically in the past 10 years and the pricing landscape continues to change, creating uncertain ground beneath developers’ feet. At the BioFuture conference in New York, a panel discussed how big and small companies go about their pricing strategies and build educated guesses into how that strategy might work out in the market.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725077</guid>
      <pubDate>Wed, 15 Oct 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725077-biofuture-2025-the-challenge-of-accurate-drug-pricing</link>
    </item>
    <item>
      <title>IRA forecloses Novo Nordisk challenge to Medicare negotiations</title>
      <description>
        <![CDATA[Like the federal district court before it, the U.S. Court of Appeals for the Third Circuit said it lacks jurisdiction to rule on the merits of Novo Nordisk A/S’ claim that the CMS violated the Inflation Reduction Act (IRA) when it treated six of the company’s insulin aspart products as one negotiation-eligible single-source drug.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724853</guid>
      <pubDate>Tue, 07 Oct 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724853-ira-forecloses-novo-nordisk-challenge-to-medicare-negotiations</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Fiasp.webp?t=1759872739" type="image/jpeg" medium="image" fileSize="93003">
        <media:title type="plain">Fiasp </media:title>
      </media:content>
    </item>
    <item>
      <title>Geneoscopy seeks coverage for Colosense, but specificity a problem</title>
      <description>
        <![CDATA[The market for colorectal cancer screening tests seems poised to heat up considerably with a recent request for Medicare coverage for Genoscopy’s Colosense test, but some who commented on the proposal have misgivings about the lower level of specificity seen in the Colosense relative to the Cologuard.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724476</guid>
      <pubDate>Wed, 01 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724476-geneoscopy-seeks-coverage-for-colosense-but-specificity-a-problem</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/1-24--Geneoscopy-RNA-FIT-test.webp?t=1759351245" type="image/png" medium="image" fileSize="1421357">
        <media:title type="plain">Geneoscopy RNA-FIT-test</media:title>
        <media:description type="plain">Geneoscopy's at-home screening test for the detection of colorectal cancer. Credit: Geneoscopy</media:description>
      </media:content>
    </item>
    <item>
      <title>Palmetto seeks to block coverage of electroporation for cancer</title>
      <description>
        <![CDATA[Palmetto GBA, the Medicare administrative contractor for most of the southeastern U.S., has opened a coverage analysis for the use of irreversible electroporation for a variety of cancers, but Palmetto has made it clear that it is unwilling to cover the procedure pending additional evidence.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724466</guid>
      <pubDate>Tue, 30 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724466-palmetto-seeks-to-block-coverage-of-electroporation-for-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/CMS-medicare-reimbursement.webp?t=1588869757" type="image/png" medium="image" fileSize="1528480">
        <media:title type="plain">Medicare puzzle</media:title>
      </media:content>
    </item>
    <item>
      <title>GAO acknowledges resource constraints in analysis of Medicare NCDs</title>
      <description>
        <![CDATA[The U.S. Government Accountability Office said in a recent report that the Medicare national coverage determination process could use a few adjustments, but the report also pointed to significant resource problems associated with the process, a source of drag that only Congress can fix.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723724</guid>
      <pubDate>Wed, 10 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723724-gao-acknowledges-resource-constraints-in-analysis-of-medicare-ncds</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/US-capital-washington-congress-government.webp?t=1588689267" type="image/png" medium="image" fileSize="2212023">
        <media:title type="plain">U.S. Capitol building</media:title>
      </media:content>
    </item>
    <item>
      <title>Imbalance seen in skin substitute use for Medicare beneficiaries</title>
      <description>
        <![CDATA[The U.S. Office of Inspector General posted an analysis of Medicare spending on skin substitutes, remarking that the data suggest a disproportionate use of these products for patients enrolled in fee-for-service (FFS) care.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723704</guid>
      <pubDate>Mon, 08 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723704-imbalance-seen-in-skin-substitute-use-for-medicare-beneficiaries</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/CMS-medicare-reimbursement.webp?t=1588869757" type="image/png" medium="image" fileSize="1528480">
        <media:title type="plain">Medicare puzzle</media:title>
      </media:content>
    </item>
    <item>
      <title>MedPAC anticipates doubling of Medicare spending by 2032</title>
      <description>
        <![CDATA[The Medicare Payment Advisory Commission said in a recent report that Medicare spending in the U.S. is poised to nearly double to $1.9 trillion over the coming eight years, a figure that is likely to apply ever-increasing price pressures on makers of devices, diagnostics and pharmaceuticals.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723538</guid>
      <pubDate>Thu, 21 Aug 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723538-medpac-anticipates-doubling-of-medicare-spending-by-2032</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/thumb/US-health-flag-medicare.webp?t=1572450772" type="image/png" medium="image" fileSize="616388">
        <media:title type="plain">US-health-flag-medicare.png</media:title>
      </media:content>
    </item>
    <item>
      <title>MedPAC anticipates doubling of Medicare spending by 2032</title>
      <description>
        <![CDATA[The Medicare Payment Advisory Commission said in a recent report that Medicare spending in the U.S. is poised to nearly double to $1.9 trillion over the coming eight years, a figure that is likely to apply ever-increasing price pressures on makers of devices and diagnostics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723184</guid>
      <pubDate>Wed, 20 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723184-medpac-anticipates-doubling-of-medicare-spending-by-2032</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/thumb/US-health-flag-medicare.webp?t=1572450772" type="image/png" medium="image" fileSize="616388">
        <media:title type="plain">US-health-flag-medicare.png</media:title>
      </media:content>
    </item>
    <item>
      <title>TEAM proposal beefed up in Medicare inpatient final for FY 2026</title>
      <description>
        <![CDATA[The U.S. Centers for Medicare & Medicaid Services adopted several significant policy changes in the Medicare inpatient final rule for fiscal 2026, which includes a larger rate bump for hospitals than seen in the draft. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/722653</guid>
      <pubDate>Tue, 05 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722653-team-proposal-beefed-up-in-medicare-inpatient-final-for-fy-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/CMS-medicare-reimbursement.webp?t=1588869757" type="image/png" medium="image" fileSize="1528480">
        <media:title type="plain">Medicare puzzle</media:title>
      </media:content>
    </item>
    <item>
      <title>CMS revisits coverage criteria for Parkinson’s, essential tremor</title>
      <description>
        <![CDATA[ An advisory committee for the U.S. Centers for Medicare & Medicaid Services endorsed a series of patient- and clinician-reported outcomes that might not be reflected in the evidentiary bases for currently available technologies. This development suggests some manufacturers will have to conduct new studies of their devices in order to sustain Medicare coverage.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722532</guid>
      <pubDate>Mon, 28 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722532-cms-revisits-coverage-criteria-for-parkinsons-essential-tremor</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/CMS-logo-and-website.webp?t=1689968782" type="image/jpeg" medium="image" fileSize="122536">
        <media:title type="plain">CMS logo and website</media:title>
      </media:content>
    </item>
  </channel>
</rss>
